This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
That was the question on the minds of a lot of health care professionals, public policy leaders, public health officials, and select politicians going into the first meeting of the new Advisory Committee on Immunization Practices (ACIP) in June 2025.
Prior to October 2024, the Advisory Committee on Immunization Practices (ACIP) recommended use of a PCV only for all adults aged 65 years and older, including those aged 19 to 64 years with risk conditions for pneumococcal disease.
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
Animals can be inaccurate testing models for human treatments, especially for disease states involving a human immune response, such as in cancer. 4 Testing also causes stress on the animals, leading to increased immune or biological responses and confounding disease data outcomes.
Furthermore, delays in medication access can exacerbate chronic conditions, such as diabetes, hypertension, and asthma, leading to increased hospitalization rates. The lack of access to immunization services may lead to lower vaccination rates and vulnerabilities to infectious diseases in these communities.
Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. 1 The US also reported the highest rates of hospitalizations and outpatient visits for flulike illnesses in 15 years.
1 Population cohorts included adults ages 65 or older enrolled in Medicare and adults ages 19 to 64 years enrolled in Medicaid and deemed eligible for pneumococcal vaccination based on Advisory Committee on Immunization Practices recommendations. 1 Medicare enrollees were examined first.
1 Howard’s team built their telehealth service in collaboration with hospitals and health systems, especially to tackle the issue of hospital readmissions for Medicare and Medicaid patients—each of which can cost hospitals thousands of dollars.
Secondary outcomes included rates of specialist referrals and asthma-related emergency department (ED) visits or hospitalizations. Asthma exacerbations requiring acute care were rare but notable: 1 patient visited the ED, and 3 were hospitalized, all of whom were in the track 2 group.
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. 4 PRACTICE INTERVENTIONS The public has increasingly learned that pharmacists and pharmacy technicians are leaders in primary prevention.
Klein, MD, FRCP (C), FACC, FAHA, FASE, FESC, director at Pericardial Disease Center and professor of medicine, and Sean Krohn, PharmD, CSP, MSCS, lead clinical pharmacist, specialty pharmacy, discussed a complex case of severe pericarditis in an elderly patient who could not tolerate traditional treatments like NSAIDs or colchicine.
During the session “Collaborative Practice, Statewide Protocols, and Independent Prescriptive Authority: How Pharmacy is Expanding Services to Increase Access to Patients,” Klepser highlighted the importance of moving beyond product dispensing to provide higher-level services, such as immunizations and medication therapy management.
The study aimed to evaluate both safety and preliminary efficacy outcomes, with a specific focus on hematologic toxicity, pharmacokinetics, and immune system effects. Flow cytometry data indicated no significant increases in immune checkpoint markers typically associated with T-cell exhaustion.
TOC pharmacists enhance medication management, reducing errors and improving patient outcomes through comprehensive care transitions. The study underscores the importance of GDMT at discharge and the potential for pharmacy models to improve healthcare metrics and hospital revenue.
link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!
SHOW MORE Avatrombopag gains FDA approval for pediatric ITP treatment, offering a new oral option for managing chronic thrombocytopenia in children. In 2019, the FDA approved avatrombopag’s expanded indication for treatment of adults with chronic immune thrombocytopenia (ITP) that hasn't responded satisfactorily to a previous therapy.
Yet, despite growing awareness, HFpEF remains difficult to manage due to nonspecific symptoms, limited clinical trial data, and inconsistencies in diagnosis. To me, it’s positioning this in terms of how quickly these patients benefit from it, and if it’s 7 days then in my opinion, start it in the hospital.”
REMS ensured drug safety by requiring certified hospitals to have tocilizumab for severe adverse events management. Increased experience in managing CAR T therapy toxicities has led to the removal of REMS, facilitating broader access.
SHOW MORE Administering influenza, COVID-19, and RSV immunizations at the same time may improve vaccine uptake. Pediatric vaccination laws vary, but pharmacists play a crucial role in educating families about vaccines like MMR, Tdap, and HPV. Before autumn approaches, start thinking about respiratory vaccines.
John’s University – College of Pharmacy and Health Sciences and practices as an infectious diseases pharmacist at NYC Health + Hospitals/Elmhurst in Elmhurst, New York. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
And that's a challenge, because in some ways, when they come in the hospital—don’t quote me on this—but they kind of can get dropped off and let the nurses and the team take care of them, and then pick them up when they're done. There was some of that kind of selling them on the idea.
SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization. The study's primary objective was to assess reversion rates to Humira, with 9% reverting after three months, while 91% remained on biosimilars or switched to alternatives.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content